A recent court decision has been widely applauded as a pathway to abolishing human gene patents. But a closer look shows that getting rid of gene patents would probably be a big mistake.

The controversy over aspects of the House health care legislation that have been inappropriately equated with "death panels" has obscured the real problems with these provisions.

Democrats have made clear that the lifesaving drug industry will soon face politically inspired assaults.

Targeted biotech drugs that attack specific biological molecules that cause disease are bringing new benefitsand fomentingpricing dynamics different from those of traditional drugs.

This piece reviews earlier work on international pharmaceutical prices and then brings to bear a data set that permits us to explore questions not previously addressed.

It is becoming increasingly clear that the initial impact of President Obama's health care reform will be to raise the cost of health insurance and the number of uninsured Americans.

AEI's Scott Gottleib, M.D., comments on President Obama's health care plan.

Despite President Obama's promise that medical care would not be rationed under his health care plan, this month the administration dispatched Department of Justice lawyers into federal court to fight a patient for the authority to do just that.